Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Human Genome Sciences Initiates Clinical Trial For HGS1029
Human Genome Sciences (HGS) and Aegera Therapeutics (Aegera) have reported that HGS has initiated dosing in a Phase 1 clinical trial to evaluate the safety and tolerability of
Human Genome Sciences (HGS) and Aegera Therapeutics (Aegera) have reported that HGS has initiated dosing in a Phase 1 clinical trial to evaluate the safety and tolerability of
Raptor Pharmaceutica (Raptor) has reported positive clinical trial data on NGX426, the company’s orally administered, non-opioid, AMPA/kainate receptor antagonist. The results of the study suggested that NGX426 could
AkzoNobel has agreed to acquire Penford’s Australian specialty grain wet milling and manufacturing facility in Lane Cove, to boost the supply capability of its National Starch business in
Inovio Biomedical has reported that a combination of synthetic consensus H1N1, H2N2, H3N2, and H5N1 influenza vaccine candidates achieved protective antibody responses against several different influenza sub-types and
Circassia has reported positive results from a recently completed phase II clinical study of ToleroMune cat allergy therapy, which successfully identified the optimal dosing regimens to progress into
Roche has established Roche Pharma Partnering Asia Office in China on November 1, 2009. The New facility will help create network alliances worldwide. Reportedly, the move is a
Amgen has licensed the exclusive right to use the ImmunoGen’s maytansinoid Targeted Antibody Payload (TAP) technology to develop anticancer therapeutics for an undisclosed target. This is the second
The company believes that the test will provide early and sensitive diagnosis of myocardial infarction and risk stratification for acute coronary syndromes William Moffitt, president and chief executive
ScinoPharm has received the Potent Compound Safety Certification from SafeBridge Consultants. The company claims that, with a cGMP manufacturing facility designed to manufacture cytotoxic and high potency compounds,
Soligenix, formerly known as Dor BioPharma, has formed a consortium to develop thermostable technology to advance RiVax and other rapidly acting vaccines. The company has received a $9.4m